Tag
This randomized trial compares aflibercept monotherapy versus combined with reduced-fluence photodynamic therapy for PCV, highlighting OCTA metrics that predict polypoidal lesion closure and treatment response over 52 weeks.
This review synthesizes evidence on PRN aflibercept treatment after complete polypoidal regression in PCV, highlighting recurrence rates, visual outcomes, and potential OCT biomarkers guiding individualized management.
This study found that younger age, better baseline vision, smaller hemorrhage size, and thicker subfoveal choroid predicted better 1-year visual outcomes after fovea-involving submacular hemorrhage from nAMD or PCV.
This post hoc analysis of the PULSAR trial reveals that aflibercept 8 mg provides noninferior visual outcomes and comparable anatomic regression to standard 2 mg dosing in PCV patients, while allowing for significantly extended treatment in
